Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Bret Edward Buckley Friday"'
Autor:
Mario E. Lacouture, Bret Edward Buckley Friday, Stephan D. Thomé, Jill Piens, Amanda O’Connor, Charles L. Loprinzi, David Zahrieh, Deanne Smith, Terra Register, Shaylene A. McCue, Susan Young, Elizabeth J. Cathcart-Rake
Publikováno v:
Supportive Care in Cancer. 29:6253-6258
To describe the natural history of nasal vestibulitis in patients receiving taxane chemotherapy, including incidence, severity, and associated symptoms. Eligible patients with minimal or no baseline nasal symptoms were enrolled in this natural histor
Autor:
Andrew Rudberg, Bret Edward Buckley Friday, Catherine McCarty, Paula Termuhlen, Sam Friedrichsen, Sara Richter
Publikováno v:
Journal of Clinical Oncology. 40:1526-1526
1526 Background: Following the onset of the COVID-19 pandemic in March 2020, there was a drastic reduction in elective procedures, including screening mammograms. This was accompanied by a precipitous drop in the number of breast cancer diagnoses in
Autor:
Jann Nagina Sarkaria, Karla V. Ballman, Sani Haider Kizilbash, Erik P. Sulman, Caterina Giannini, Sandeep H. Mashru, David Eric Piccioni, Bret Edward Buckley Friday, Jesse G. Dixon, Brian Kabat, Nadia N. Laack, Leland Hu, Priya Kumthekar, Benjamin M. Ellingson, S. Keith Anderson, Evanthia Galanis
Publikováno v:
Journal of Clinical Oncology. 40:2001-2001
2001 Background: PolyADP-ribose polymerase (PARP) is an important modulator of DNA repair following temozolomide (TMZ) therapy. Pre-clinical testing demonstrated significant survival benefit for the combination of TMZ and PARP inhibitor veliparib in
Autor:
Colleen M. Renier, Tiana Luczak, Stephen C. Waring, Bret Edward Buckley Friday, Paul J Schillo
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(4)
Introduction Pharmacogenetics, in hand with precision medicine in oncology, represents an opportunity to holistically tailor a patient’s treatment regimen using both somatic and germline variants to improve efficacy and decrease toxicity. Colorecta
Autor:
Aaron Mammoser, Alyx B. Porter, Bret Edward Buckley Friday, Ugonma Chukwueke, Shawn L. Hervey-Jumper
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 41
It is widely recognized that subspecialized multidisciplinary care improves neuro-oncology outcomes. Optimizing patient outcomes relies on the expertise of the treating physicians, neuroradiology and neuropathology, and supportive services familiar w
Autor:
Erik Asmus, Claudine Isaacs, Donald B. Wender, Lauren J. Rogak, Ethan Basch, Bret Edward Buckley Friday, DeQuincy Andrew Lewis, Thomas H. Openshaw, Gini F. Fleming, Alvaro Moreno-Aspitia, Amylou C. Dueck, Minetta C. Liu, Kendrith M. Rowland, Nguyet A. Le-Lindqwister, Alan P. Lyss, Ashley Frith, John T. Cole, Anthony J. Jaslowski, Douglas Weckstein, David W. Hillman
Publikováno v:
Journal of Clinical Oncology. 38:1016-1016
1016 Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 trial of E vs capecitabine in advanced BC treated w
Publikováno v:
Neuro Oncol
INTRODUCTION Glioblastoma (GBM) is an aggressive primary brain tumor with a dismal prognosis. Overall survival rates have been correlated to initial tumor resection making improved imaging techniques necessary for improved patient outcomes. Functiona
Autor:
Jann N. Sarkaria, Brett L. Carlson, Cheyne Kurokawa, Cory Allen, Mark A. Schroeder, Ianko D. Iankov, Hirosha Geekiyanage, Katrina K. Bakken, A B D'Assoro, Bret Edward Buckley Friday, Evanthia Galanis, Jeffrey Ecsedy
Publikováno v:
Journal of neuro-oncology. 131(1)
Aurora A Kinase (AURKA), a member of the serine/threonine kinase family, plays a critical role in cell division, and it is widely overexpressed in a variety of tumors including glioblastoma (GBM). Alisertib (MLN8237) is an orally administered selecti
Autor:
Bret Edward Buckley Friday, Jennifer Benedict, Ronald Regal, Brian Johnson, Rajshekhar Chakraborty
Publikováno v:
Journal of Clinical Oncology. 35:e18154-e18154
e18154 Background: Due to an increase in the elective decision to pursue contralateral prophylactic mastectomy (CPM), the incidence of bilateral mastectomy (BM) with/without postmastectomy reconstruction (R) [BM+/-R] has increased in the last decade.
Autor:
Bret Edward Buckley Friday, S. Keith Anderson, Chunrong Yu, Miroslaw Mazurczak, Jan C. Buckner, Howard Gross, Eduardo Pajon, Francois J. Geoffroy, Kurt A. Jaeckle, Evanthia Galanis, John Schwerkoske, Caterina Giannini
Glioblastoma (GBM) is a refractory malignancy. Despite surgical resection, external beam radiation therapy, and chemotherapy, median survival is only 15–18 months.1,2 There is an urgent need to develop novel therapeutic strategies for this disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842ebc009627f9c40707605665cd4c0b
https://europepmc.org/articles/PMC3266383/
https://europepmc.org/articles/PMC3266383/